Former President Trump has announced a new deal that will allow Medicare to cover the cost of Ozempic, a popular weight-loss drug. While this move could help many Americans manage their health, it raises concerns about the impact on the national debt, which is already a significant issue. Critics argue that this decision could exacerbate the financial burden on the country, highlighting the ongoing debate about healthcare funding and fiscal responsibility.

The Trump administration's recent assertion that trillions in tariff revenue are merely 'incidental' raises eyebrows and concerns about the implications for the economy and trade policy. This claim suggests a shift in narrative regarding the administration's approach to tariffs, which have been a contentious issue. Understanding the impact of these tariffs is crucial as they affect everything from consumer prices to international relations.

Former President Donald Trump has announced a significant deal aimed at reducing the prices of obesity drugs to as low as $150 a month. This move is crucial as it addresses the rising obesity rates and the financial burden many face when seeking treatment. By making these medications more affordable, Trump hopes to improve access to essential healthcare for millions struggling with obesity, ultimately promoting better health outcomes and reducing healthcare costs in the long run.

Businesses are feeling the pinch from rising costs due to Trump's tariffs, and many are passing these expenses onto consumers. This situation raises concerns about the impact on everyday prices and whether the Supreme Court can intervene to alleviate the burden. It's a critical issue that affects everyone, as higher prices can strain household budgets and influence economic stability.

In a significant move to make weight-loss medications more affordable, President Donald Trump has announced new agreements with pharmaceutical giants Eli Lilly and Novo Nordisk. This initiative aims to lower the prices of these essential drugs, which could greatly benefit many Americans struggling with obesity and related health issues. By addressing the cost barriers, the administration hopes to improve access to effective treatments and promote better health outcomes across the nation.

In a significant move, Trump has expanded the list of critical minerals to include copper, metallurgical coal, and uranium. This decision is crucial as it aims to bolster the U.S. supply chain for essential resources, reducing dependency on foreign imports. By prioritizing these minerals, the administration is not only addressing national security concerns but also promoting economic growth and job creation in the mining sector.

Novo Nordisk has announced that it anticipates a decline in global sales by low single digits in 2026. This projection is significant as it reflects potential challenges the company may face in maintaining its market position and revenue growth. Investors and stakeholders will be closely monitoring how Novo Nordisk plans to navigate this downturn and what strategies they will implement to counteract the expected decline.

Eli Lilly and Novo Nordisk have reached a significant agreement with the Trump administration to reduce prices on their popular weight-loss medications. This deal, announced during a White House event, aims to provide Medicare patients with better access to these essential drugs, making them more affordable for older Americans. This move is crucial as it addresses the rising costs of healthcare and ensures that more people can benefit from effective weight-loss treatments.